The multidrug resistance protein 2 (MRP2/ABCC2) mediates the biliary excretion of glucuronide and glutathione conjugates of endogenous and exogenous compounds. We examined the activation of human MRP2-mediated ATP-dependent transport by the choleretic bile salt ursodeoxycholic acid (UDC) and its taurine and glycine amidates in Sf9 cell membranes expressing MRP2 using ␤-estradiol 17-(␤-D-glucuronide) (E 2 17G) and ␤-estradiol 3-(␤-D-glucuronide) (E 2 3G) as substrates. MRP2 transported E 2 3G via classic Michaelis-Menten kinetics (K m ϭ 122 M; V max ϭ 3.0 nmol/mg/min), whereas E 2 17G transport showed positive cooperativity (Hill slope, 2.15; K m ϭ 75 M; V max ϭ 3.8 nmol/mg/min). UDC, tauroursodeoxycholate, and glycoursodeoxycholate (80 -100 M) maximally stimulated E 2 3G transport 9-, 7.9-, and 3.6-fold, respectively, whereas higher concentrations (1-2 mM) inhibited transport. At low (0.3 M) concentrations, tauroursodeoxycholate was transported only in the presence of E 2 17G or E 2 3G, but not other MRP2 substrates such as methotrexate, leukotriene C 4 , or S-methylglutathione. Kinetic analysis of higher concentrations of tauroursodeoxycholate transport by MRP2 showed positive cooperativity (Hill slope, 1.84; K m ϭ 127 M; V max ϭ 779 pmol/mg/ min). Taurocholate (2-100 M) was not detectably transported by MRP2 either alone or in the presence of E 2 17G but was transported in the presence of E 2 3G. Thus, UDC, tauroursodeoxycholate, and glycoursodeoxycholate activated MRP2 transport. Tauroursodeoxycholate was transported by MRP2 and demonstrated positive cooperativity, identifying it as the second MRP2 substrate able to stimulate its own transport. The data suggest MRP2 binding sites that can require specific complementarities between substrates and modulators of MRP2-mediated transport.
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The human 190-kDa multidrug resistance protein MRP2 (gene symbol ABCC2) is a member of the subfamily C of the superfamily of ATP-binding cassette superfamily of transport proteins. It mediates the cellular efflux of glucuronide, glutathione, and sulfate conjugates of many endogenous substrates and xenobiotics, including drugs, and its location on the canalicular domain of the hepatocyte ensures their efficient biliary excretion. Several recent studies have demonstrated activation ABC transporters including P-glycoprotein and MRPs 1, 2, and 3 (Shapiro et al., 1999; Leslie et al., 2001; Maki et al., 2003; Zelcer et al., 2003) . Transport activation has been suggested to occur through allosteric activation, in which the activating agent is not transported, or by a cotransport mechanism. For example, ethinyl-estradiol-3-sulfate allosterically activates MRP2 and MRP3 transport activity but is not transported by MRP2 or MRP3 (Chu et al., 2004) . In contrast, sulfinpyrazone stimulates MRP2-mediated 2,4-dinitrophenyl-S-glutathione transport, can be cotransported with glutathione by MRP2, or can be transported by MRP2 in the absence of reduced glutathione at high concentrations (Evers et al., 1998 (Evers et al., , 2000 . Glycocholate and certain bile salts also activate MRP2-mediated transport of ␤-estradiol 17-(␤-D-glucuronide) (E 2 17G) (Bodo et al., 2003) . Recently, Borst et al. (2006) have suggested several models that explain transport activation, favoring a model in which a broad-based binding site binds multiple ligands, thus enabling cooperative and/or competitive ligand interactions.
We recently found that ursodeoxycholate (ursodiol, UDC) can directly interact with MRP2 in vitro to activate its transport activity (Gerk et al., 2003) . This finding holds special interest because of the therapeutic utility of UDC in treating cholestatic liver disease, including primary biliary cirrhosis and primary sclerosing cholangitis. UDC is also used off-label to treat other cholestatic liver diseases, including intrahe-patic cholestasis of pregnancy (Paumgartner and Beuers, 2002) . UDC is conjugated with glycine or taurine in the hepatocyte to glycoursodeoxycholate (GUDC) and tauroursodeoxycholate (TUDC), respectively, and these hydrophilic bile salts become a major portion of the bile salt pool upon chronic dosing with UDC. UDC protects cholangiocytes against the detergent and toxic actions of hydrophobic bile salts and protects against apoptosis induced by bile salts; it also functions to stimulate impaired hepatobiliary secretion. This latter mechanism occurs through several modes, including transcriptional up-regulation of expression of the hepatic efflux transporters bile salt export pump (Bsep) and Mrp2 and stimulation of their insertion into the canalicular membrane (particularly by TUDC) that appears dependent on Ca 2ϩ -and protein kinase C (PKC)␣-dependent mechanisms (Paumgartner and Beuers, 2002) . E 2 17G is a naturally occurring estrogen metabolite that is used widely as a model organic anion substrate, particularly for MRP2. E 2 17G is also cholestatic, decreasing bile flow acutely and reversibly in rats (Vore, 1987) ; Mrp2-mediated transport of E 2 17G is essential for its induction of cholestasis (Huang et al., 2000) . E 2 17G cholestasis is due to the retrieval of the canalicular transporters Mrp2 and Bsep into subapical vesicles (Mottino et al., 2002; Crocenzi et al., 2003) that may be triggered through its trans-inhibition of Bsep (Stieger et al., 2000) . Mrp2 also transports glutathione into bile, and much of the bile salt-independent component of bile flow is attributable to the osmotic action of glutathione (Ballatori and Rebbeor, 1998) . Thus, modulation of MRP2 expression and activity has important potential in treating cholestatic diseases, particularly in pregnancy, where accumulation of estrogen glucuronides is thought to contribute to decreased bile secretory function. TUDC is effective in overcoming E 2 17G-induced cholestasis without having the adverse effects of the more hydrophobic taurocholate (Utili et al., 1990) .
The purpose of the present studies was to investigate the functional nature of the activation mechanism of bile salts on MRP2 transport activity. To address this issue, we overexpressed MRP2 in Sf9 insect cells and examined MRP2 transport activity in plasma membrane vesicles, in which the inside-out membrane vesicles may access ATP. As substrates, we used E 2 17G and its regioisomer, ␤-estradiol 3-(␤-D-glucuronide) (E 2 3G), which we recently showed to be an excellent substrate for rat Mrp2 . The results show that a broad range of bile salts can activate MRP2 and, importantly, that TUDC is transported by MRP2 and stimulates its own transport, as evidenced by positive cooperativity. Furthermore, the presence of estrogen glucuronides also stimulates MRP2-mediated transport of low concentrations of TUDC. These data imply that certain pairs of compounds, including bile salts, can be bound and transported in tandem by MRP2. (Roda et al., 1992) . All restriction enzymes were obtained from Invitrogen (Carlsbad, CA) except BssHII (Fisher, Pittsburgh, PA) and AvrII (New England Biolabs, Beverly, MA). The plasmid (pEF6/V5-His-TOPO; Invitrogen) containing the reference MRP2 sequence (NM_000392) was a generous gift from Dr. Richard Kim (Vanderbilt University, Nashville, TN). The plasmid was sequentially digested with SalI, NotI, and AvrII to obtain a 4.3-kb fragment (5Ј-AvrII-NotI-3Ј), lacking the 5Ј fragment (320 bases), a region of the MRP2 coding sequence including the start codon and the AvrII site. The 5Ј fragment was amplified by polymerase chain reaction using the forward and reverse primers 5Ј-AC-CGCGCGCGAATCATGCTGGAGAAGTTCTGC-3Ј and 5Ј-GATCAG-CAAAACCAGGAGC-3Ј, respectively. The 365-bp product and the pFastBac1 vector (Invitrogen) were sequentially digested with BssHII/AvrII and BssHII/NotI, respectively, isolated, and recovered. The vector and the two MRP2 fragments were ligated using T4 ligase (Promega, Madison, WI), transformed into XL-10 Gold cells, and colonies were selected by digesting miniprep DNA (Qiagen, Valencia, CA) with BamHI to find a colony yielding 0.4-, 2.5-, and 7-kb fragments. DNA from the chosen colonies was partially sequenced to verify the correct amplification and insertion of the 5Ј MRP2 fragment and transformed into DH10Bac Escherichia coli cells (Invitrogen) to recombine MRP2 into the baculovirus genome according to the manufacturer's instructions. The recombinant bacmids were amplified, sequenced (Elim Biopharmaceuticals, Hayward, CA) to confirm the presence (or absence) of MRP2, and transfected using CellFectin (Invitrogen) into Sf9 insect cells. The supernatant containing the recombinant baculovirus was harvested, amplified, and titered by a viral plaque assay. Infection conditions in Sf9 cells were optimized with respect to MRP2 protein expression and transport activity. Sf9 cells (5 ϫ 10 8 cells) in suspension culture were infected in the presence of 5% fetal bovine serum using a multiplicity of infection of six, and 48 h later, plasma membrane vesicles were isolated and stored as described previously (Ito et al., 2001b; . Expression of MRP2 was determined by Western blotting using 0.5 g of membrane protein as described for rat Mrp2 .
Materials and Methods
Membrane vesicles from Sf9 cells are a mixture of right side out and inside-out (ABC domain facing the extravesicular buffer) orientations; approximately 65% are inside out, permitting transport into the vesicles to occur in the presence of ATP (van Aubel et al., 1998) . Transport experiments were performed in a Tris-sucrose buffer (Ito et al., 2001b) , containing 5 mM ATP or AMP, 10 mM MgCl 2 , 10 mM phosphocreatine, 100 g/ml creatine phosphokinase, and unlabeled estrogen conjugates in dimethylsulfoxide (0.5%) as a vehicle. ATPdependent transport of
]TC into membrane vesicles (10 g/20 l) was measured in incubations at 37°C for 2 to 5 min, transport stopped with 3.5 ml of ice-cold stop buffer (Ito et al., 2001b) , and the mixture was quickly filtered onto Durapore 0.4-m filters (Millipore, Bedford, MA). The filters were selected due to their minimal binding of E 2 17G at low (90 nM) or high (100 M) concentrations and relatively low binding of bile salts. The filters were processed, and 3 H was detected by liquid scintillation counting, as described previously .
Transport corrected for that in the presence of AMP was termed ATP-dependent transport, whereas that corrected for background (EV) transport was termed MRP2-mediated transport . Nonlinear regression was performed on saturation data by fitting the unweighted data to the Hill equation. Other curves were unweighted for linear or nonlinear regression using Prism version 4 computer software (GraphPad, San Diego, CA) for fitting as indicated in figure legends. Data for Fig. 4 , A and B, were fitted to eq. 1 below:
where T is the observed transport activity, C is the concentration of the modulator (i.e., UDC), T 0 is the baseline transport activity, A max is the maximal activation, I max is the maximal inhibition, and K 1 and K 2 are Michaelis-Menten constants pertaining to the apparent affinity of the stimulatory and inhibitory components, respectively. This equation postulates two independent binding sites, associated with either activation (A max /K 1 ) or inhibition (I max /K 2 ). Remaining data were analyzed by one-way analysis of variance (␣ ϭ 0.05) followed by Dunnett's multiple comparison test.
Results
A single immunoreactive band corresponding to underglycosylated MRP2 was observed in Sf9 membrane vesicles infected with the baculovirus containing the full coding region of MRP2, whereas human MRP2 was absent in control (EV) membrane vesicles (Fig. 1) . Like rat Mrp2 , transport of E 2 3G by human MRP2 was linear with respect to incubation time (Fig. 2A) ; furthermore, linearity with respect to membrane protein (5-20 g) and osmotic sensitivity were established (data not shown). MRP2 transported the novel substrate E 2 3G via classic Michaelis-Menten kinetics (K m ϭ 122 Ϯ 23 M; V max ϭ 2.99 Ϯ 0.19 nmol/ mg/min; Hill slope ϭ 1), as shown in Fig. 2B .
We next determined the specificity of the interactions between physiologically relevant bile salts (100 M each) and MRP2 (Fig. 3) . All bile acids examined stimulated E 2 3G transport 2-to 5-fold, except for taurolithocholate sulfate, a sulfated bile salt with two negative charges, and an MRP2 substrate. Activation of MRP2-mediated ATP-dependent transport was not correlated (r 2 ϭ 0.19) with the bile salt hydrophobic index (Heuman, 1989 ) (data not shown).
We examined in greater depth the influence of the clinically relevant bile salts UDC, TUDC, and GUDC on MRP2-mediated ATP-dependent E 2 3G transport activity. UDC (100 M) maximally stimulated E 2 3G transport 9-fold, whereas higher concentrations inhibited transport, as determined by inspection of the data, since nonlinear regression analysis did not give a unique fit (Fig. 4A) . Because UDC is efficiently conjugated to taurine and glycine in vivo, we examined the effects of the UDC amidates, TUDC and GUDC, in greater depth (Fig. 4B) . TUDC (100 M) maximally stimulated transport (A max ) 7.9-Ϯ 0.8-fold with a K 1 of 24 Ϯ 3 M, whereas GUDC activation (3.6-Ϯ 0.5-fold) was maximal at 80 M (K 1 ϭ 17 Ϯ 5 M). Higher concentrations (up to 2 mM) of TUDC and GUDC completely inhibited E 2 3G transport (I max , 1.4 Ϯ 0.2 and 1.1 Ϯ 0.1, respectively), with K 2 values of 1520 Ϯ 400 and 610 Ϯ 230 M, respectively. These results suggest two kinetically distinct sites on MRP2 to which UDC, TUDC, and GUDC bind. In EV membrane vesicles that lack MRP2, UDC (0 -1000 M), TUDC (100 M), and GUDC (100 M) did not stimulate or inhibit E 2 3G transport or diffusion in the presence or absence of ATP (data not shown). Thus, the effects seen in Fig. 4 , A and B, could be appropriately attributed to modulation of MRP2-mediated transport activity.
MRP2-mediated transport of E 2 17G has been shown to stimulate its own transport (homotropic activation). Kinetic analysis of E 2 17G transport over a broad concentration range (1-250 M) was saturable, with evidence of positive cooperativity (Hill slope ϭ 2.1 Ϯ 0.3; K m ϭ 75 Ϯ 7 M; V max ϭ 3.8 Ϯ 0.2 nmol/mg/min), consistent with multiple interacting E 2 17G binding sites (Fig. 5) . To characterize the influence of UDC on the positive cooperativity of E 2 17G transport, we used a low concentration (30 M) of UDC that activated E 2 3G transport and a high concentration (1000 M) that inhibited E 2 3G transport. UDC (30 M) activated MRP2 but increased the apparent K m and V max estimates to 360 Ϯ 120 M and 13 Ϯ 2 nmol/mg/min, respectively; positive cooperativity was abolished as the Hill slope was decreased to 1.0 Ϯ 0.1. In contrast, 1000 M UDC competitively inhibited E 2 17G transport (K m ϭ 140 Ϯ 14 M; V max ϭ 3.5 Ϯ 0.2 nmol/mg/min), with a decrease in the Hill slope (1.2 Ϯ 0.1) (Fig. 5) .
Nonsulfated and nonglucuronidated bile salts, as monoanionic bile salts, have been shown not to be transported by MRP2 (Stieger et al., 2000) . However, their ability to stimulate MRP2 transport could be explained by an apparent cotransport model, as proposed for sulfinpyrazone and glutathione (Evers et al., 2000) and for glycocholate and E 2 17G (Bodo et al., 2003) . We therefore tested the ability of MRP2 to mediate transport of taurocholate and TUDC. Data are reported as the clearance, or flux divided by concentration, which permits comparison of initial MRP2 transport activities for substrates of differing specific activities. [
3 H]taurocholate (2-100 M) was not transported alone or in the presence of E 2 17G (20 M); surprisingly, [ 3 H]taurocholate (2 M) was transported to a small extent in the presence of E 2 3G (50 M) (10.4 Ϯ 1.9 l/mg/min, mean Ϯ S.D.). MRP2 did not significantly transport [
3 H]TUDC (0.3 M) alone or in the presence of S-methylglutathione (3 mM, a nonreducing glutathione analog; Rius et al., 2003) or the MRP2 transport substrates leukotriene C 4 (1 M), taurolithocholate-3-sulfate (10 M), and methotrexate (100 M) (Table 1 ). However, in the presence of E 2 17G (20 M), E 2 3G (50 M), or at a higher concentration of TUDC (100 M), significant transport of [ 3 H]TUDC was observed ( Table 1 ). The clearance of [ 3 H]TUDC in the presence of E 2 3G (14.4 Ϯ 1.9 l/mg/min) thus approached the MRP2-mediated clearance of E 2 3G (20 -25 l/mg/min).
To verify MRP2-mediated transport of TUDC, we demonstrated that [ 3 H]TUDC transport was linear with time ( Fig. 6A ) and occurred into an osmotically sensitive space (Fig. 6B) , consistent with transport rather than binding. [ 3 H]TUDC transport was saturable and best fit to the Hill equation (Fig. 6C) , yielding V max of 779 Ϯ 106 pmol/mg/min and K m of 127 Ϯ 26 M, and showed clear evidence of positive cooperativity (Hill slope ϭ 1.84 Ϯ 0.36). These data indicate that TUDC is a substrate of MRP2 and is also able to stimulate its own transport.
Discussion
The present data demonstrate that physiologically and pharmacologically relevant bile salts, specifically UDC and 
Treatment
Clearance (MeanϮ S.D.)
14.4 Ϯ 1.9* LTC 4 , leukotriene C 4 ; MTX, methotrexate; MeSG, S-methyl-glutathione; TLCS, taurolithocholate sulfate.
* Transport in MRP2-expressing membrane vesicles significantly different (P Ͻ 0.05) from that in control (EV) membrane vesicles. its amidates, TUDC and GUDC, activate MRP2-mediated transport. The data further demonstrate that TUDC is transported by MRP2, so that it is both a modulator and a substrate of MRP2. We placed particular emphasis on ursodeoxycholates because UDC is used to treat cholestatic liver disease and is amidated to the active metabolites TUDC and GUDC (Paumgartner and Beuers, 2002) . The effects of UDC, TUDC, and GUDC on transport were biphasic. At low concentrations (Յ100 M), these bile salts strongly increased MRP2-mediated transport activity; however, at higher concentrations, these bile salts decreased transport activity, even below baseline values, as seen with GUDC. This latter effect is consistent with competitive inhibition because UDC increased the K m for E 2 17G transport, without decreasing V max (Fig. 2D) . These data indicate that UDC and its amidates are both able to stimulate transport and to compete with transport substrates at one (or more) site(s) on MRP2. The effects of TUDC, GUDC, and UDC on MRP2-mediated transport of E 2 3G were qualitatively similar, with TUDC having the greatest maximal activation. These effects are unlikely to reflect nonspecific perturbations on membranes since TUDC does not directly stabilize membranes (Heuman et al., 1996) , and neither 100 M nor 2 mM TUDC significantly altered sucrose permeability under the present experimental conditions (P. M. Gerk, unpublished data). The ability to competitively inhibit MRP2-mediated transport suggested that these monoanionic bile salts might therefore also be MRP2 substrates. Consistent with these findings, we showed directly that TUDC is an MRP2 substrate.
These data are consistent with the current model of multiple overlapping binding sites on MRP2 (Ito et al., 2001a; Bodo et al., 2003; Zelcer et al., 2003) , where transport activity can be markedly stimulated by numerous endogenous and exogenous compounds. Thus, taurocholate, glycocholate, glycochenodeoxycholate, taurochenodeoxycholate, and taurodeoxycholate can activate transport of E 2 17G by MRP2 expressed in Sf9 cell membrane vesicles; glycocholate may also be transported in the presence of E 2 17G (Bodo et al., 2003; Zelcer et al., 2003) . Here, we examined a range of concentrations of UDC, TUDC, and GUDC to provide an in-depth mathematical assessment of the nature of the binding and to obtain good fits to a pharmacologically meaningful model. We also corrected for endogenous transport (i.e., transport in EV membranes) to obtain more accurate kinetic parameters of the modulation of MRP2-mediated transport. The present data confirm the previous studies (Bodo et al., 2003; Zelcer et al., 2003) and provide additional insight regarding the mechanism of activation of MRP2 by the bile salts.
The literature is replete with examples of compounds that stimulate MRP2 transport, whereas the number of substrates whose transport can be stimulated is more restricted. To date, E 2 17G is the only substrate also able to stimulate its own transport; the present data clearly identify TUDC as a second such substrate. Borst et al. (2006) have proposed a model whereby compounds can be transported and/or stimulate MRP2-mediated transport. In this model, MRP2 contains a substrate binding site (S) to which a substrate binds and is transported. An additional site can accommodate compounds (M) that modulate/stimulate transport at the S site, thus leading to heterotropic activation. If the substrate can also bind the modulatory site, it can stimulate its own transport, termed homotropic activation, which is detected as positive cooperativity, as seen here for TUDC. The present data require a more complex model in that some MRP2 substrates (e.g., methotrexate, leukotriene C 4 ) must bind to a distinct site(s) that does not participate in the interaction between these bile salts and the estrogen glucuronides. The present data also indicate that there are specific complementarities between modulators and substrates such that a modulator can stimulate transport of some substrates, but not others. Thus, E 2 3G does not stimulate its own transport but does stimulate that of taurocholate and TUDC. Although E 2 17G can stimulate its own transport and that of TUDC, it does not stimulate transport of taurocholate.
The physical nature of the modulatory and substrate binding sites is not known, and it is difficult to predict whether modulators and substrates bind to sites spatially relatively far apart or very close, such as in different areas of a single large site. Three ligand molecules bind simultaneously in a single large binding site of the E. coli multidrug efflux pump AcrB due to their aromatic stacking (Yu et al., 2003) . In a potentially analogous manner, our data show that estrogen glucuronides and amidated bile salts can bind simulta- neously to MRP2 site(s), resulting in a fully occupied transporter that then operates more efficiently.
Although MRP2 has classically been considered unable to transport bile salts containing a single anionic charge, e.g., taurocholate (Stieger et al., 2000) , other members of the Mrp family of transporters, i.e., Mrp3 and MRP4, transport taurocholate (Ito et al., 2001b; Rius et al., 2003) . Site-directed mutagenesis studies of Mrp2 demonstrated that cationic Arg residues in transmembrane domains 11 (Arg586) and 14 (Arg1096) prevent Mrp2-mediated transport of TC; mutation of these Arg to a neutral amino acid such as Leu led to acquisition of TC transport activity (Ito et al., 2001b) . Conversely, substitution of Leu at the comparable 1084 of rat Mrp3 with Lys resulted in the loss of TC transport activity. MRP4 also transports TC, but only in the presence of glutathione or its analogs (Rius et al., 2003) . These authors further demonstrated that TC stimulated transport of [ 3 H]glutathione. UDC competitively inhibited MRP4-mediated TC transport in the presence of S-methyl-glutathione, whereas cGMP and cAMP, MRP4 substrates, had no effect, suggesting that bile salts and the cyclic nucleotides are transported from distinct transport sites. Taken together, these data indicate that subtle but important differences in the substrate binding sites for MRP2, Mrp3, and MRP4 confer the ability to transport bile salts.
UDC stimulates hepatobiliary secretion in several model systems (Paumgartner and Beuers, 2002) . Treatment of mice or rats with UDC increases expression of Bsep and Mrp2 mRNA; however, other bile salts have similar effects (Fickert et al., 2001 ). In addition, TUDC stimulates the exocytic insertion of carrier proteins Bsep and Mrp2 into the apical membrane of the hepatocyte, thus stimulating biliary secretion. Roles for cytosolic free intracellular calcium and translocation of the Ca 2ϩ -sensitive ␣-isoform of PKC to hepatocyte membranes and activation of membrane-bound PKC have been demonstrated in TUDC-induced stimulation of Mrp2 transport in the cholestatic liver (Beuers et al., 2001) . Our data are the first to suggest that UDC, TUDC, and GUDC increase hepatobiliary secretion by directly enhancing the transport activity of MRP2.
The present results have important implications for the understanding and treatment of cholestatic liver disease. UDC is effective in the treatment of a number of cholestatic liver diseases, such as primary biliary cirrhosis (Paumgartner and Beuers, 2002) , and is effective in resolving or improving the liver function and clinical status of children with progressive familial intrahepatic cholestasis (Jacquemin et al., 1997) . Early studies noted decreased clearance of bile acids following administration of UDC to subjects with Dubin Johnson Syndrome, an inherited autosomal recessive disorder characterized by the absence of functional MRP2 protein (Kawasaki et al., 1981) . In a recent case study, Corpechot et al. (2006) noted a sharp increase in serum bile acid levels and no improvement in bilirubin concentration following UDC treatment of a patient with confirmed Dubin Johnson Syndrome (Corpechot et al., 2006) . These data support the hypothesis of an important role for MRP2 in the biliary excretion of bile salts.
UDC is also administered to patients with intrahepatic cholestasis of pregnancy and has been shown to improve maternal symptoms, without adverse fetal effects (Mullally and Hansen, 2002) . Intracellular accumulation of cholestatic estrogen glucuronide conjugates, such as E 2 17G and estriol-16␣-glucuronide, has been postulated to contribute to intrahepatic cholestasis of pregnancy (Vore, 1987) . E 2 17G cholestasis is due to the retrieval of the canalicular transporters Mrp2 and Bsep (Mottino et al., 2002; Crocenzi et al., 2003) and may be facilitated by E 2 17G trans-inhibition of Bsep (Stieger et al., 2000) . UDC and its amidates could activate MRP2-mediated efflux of E 2 17G present in the hepatocyte into bile, while simultaneously increasing bile flow, thus decreasing intracellular concentrations and preventing retrieval of MRP2 and BSEP (Mottino et al., 2002; Crocenzi et al., 2003) , as well as diluting biliary concentrations of E 2 17G so as to overcome any trans-inhibition of BSEP (Stieger et al., 2000) . Although the free concentration of bile acids in the hepatocyte under physiological conditions or following UDC therapy is not known, they are thought to be extremely low (Bachrach and Hofmann, 1982) , and certainly well below the maximal activation concentration of 100 M.
In summary, the present studies demonstrate that UDC, TUDC, and GUDC stimulate MRP2-mediated transport of E 2 3G and E 2 17G. Importantly, MRP2 transports TUDC, and this transport demonstrates homotropic activation, as shown by a Hill coefficient significantly greater than 1. Further mechanistic studies are required to understand the structural features of MRP2 that lead to its activation, as well as clinical studies that exploit this property to develop additional therapeutic approaches for cholestatic liver disease.
